Skip to main content
About HEC About HEC
Summer School Summer School
Faculty & Research Faculty & Research
Master’s programs Master’s programs
Bachelor Programs Bachelor Programs
MBA Programs MBA Programs
PhD Program PhD Program
Executive Education Executive Education
HEC Online HEC Online
About HEC
Overview Overview
Who
We Are
Who
We Are
Egalité des chances Egalité des chances
HEC Talents HEC Talents
International International
Campus
Life
Campus
Life
Sustainability Sustainability
Diversity
& Inclusion
Diversity
& Inclusion
Stories Stories
The HEC
Foundation
The HEC
Foundation
Summer School
Youth Programs Youth Programs
Summer programs Summer programs
Online Programs Online Programs
Faculty & Research
Overview Overview
Faculty Directory Faculty Directory
Departments Departments
Centers Centers
Chairs Chairs
Grants Grants
Knowledge@HEC Knowledge@HEC
Master’s programs
Master in
Management
Master in
Management
Master's
Programs
Master's
Programs
Double Degree
Programs
Double Degree
Programs
Bachelor
Programs
Bachelor
Programs
Summer
Programs
Summer
Programs
Exchange
students
Exchange
students
Student
Life
Student
Life
Our
Difference
Our
Difference
Bachelor Programs
Overview Overview
Course content Course content
Admissions Admissions
Fees and Financing Fees and Financing
MBA Programs
MBA MBA
Executive MBA Executive MBA
TRIUM EMBA TRIUM EMBA
PhD Program
Overview Overview
HEC Difference HEC Difference
Program details Program details
Research areas Research areas
HEC Community HEC Community
Placement Placement
Job Market Job Market
Admissions Admissions
Financing Financing
Executive Education
Home Home
About us About us
Management topics Management topics
Open Programs Open Programs
Custom Programs Custom Programs
Events/News Events/News
Contacts Contacts
HEC Online
Overview Overview
Degree Program Degree Program
Executive certificates Executive certificates
MOOCs MOOCs
Summer Programs Summer Programs
Youth programs Youth programs
Instant

Clinical Trial Transparency is Good for Public Health... and for Investors

Accounting
Published on:

When it comes to life-saving – but also potentially risky – drugs, there is no such thing as too much information. Increasing transparency about clinical trials benefits public health, as a study of US regulation in the pharmaceutical sector shows. The three researchers behind this innovative study argue that transparency and public scrutiny also bring benefits to the investors of pharmaceutical companies.

a doctor handling a bottle of COVID19 vaccine -thumbnail

Photo: ©Leigh Prather on Adobe Stock

 

Why is it important to monitor the pharmaceutical industry?

The pharmaceutical industry is a crucial sector to human life and health – not to mention a sizeable chunk of the economy (in the U.S., it alone accounts for one-fifth of the economy). While companies are expected to be upfront about a drug’s adverse effect, they ultimately hold all the cards and may choose to withhold information detrimental to drug sales, risking patients’ lives. 

 

Timely public access to clinical trial results enables medical professionals and public officials to make the right decisions on the right course of action – extremely important today in the current COVID-19 pandemic and the race to find the (best) vaccines and treatments.

 

Gambling with human lives – wouldn't it be awfully bad publicity?

Yet it has happened in the past. Take the example of Vioxx, a painkiller developed and marketed by Merck & Co. in 1999. One undisclosed side effect was an increased risk of heart attacks. As a result, Vioxx was withdrawn from the market in 2004, but not before causing coronary heart disease in at least 80,000 patients, of whom it is estimated at least 38,000 died (and also not before generating billions of dollars of revenue for Merck). In this regard, France experienced a similar scandal with the Mediator antidiabetic drug. 

the building of Merck company in South San Francisco
Merck & Co building in South San Francisco
(Photo Credits: ©Andrei on Adobe Stock)

Aren't there any public health safeguards?

Sticking to the example of the U.S., the Food and Drug Administration Modernization Act (FDAMA) of 1997 required all clinical trials to be registered with the FDA. In 2000, the government website ClinicalTrials.gov was launched, giving researchers and pharmaceutical companies a platform to post their studies. However, it was not until the Vioxx scandal that the U.S. Congress passed the Food and Drugs Administration Amendments Act (FDAAA) in 2007, which requires pharmaceutical companies to register all their clinical trials on the website ClinicalTrials.gov and publish the results of their applicable trials within a year of trial completion. 

What changed after the FDAAA came into force?

We hypothesised that increased disclosure of information would lead to economic and social benefits not only for patients but also for investors. Examining 163 pharmaceutical companies compared to other unaffected companies before and after the FDAAA came into force in 2007, we found reduced information asymmetry between the disclosing pharmaceutical company and capital market participants, the general public, academics, and practitioners after the FDAAA implementation.

Why is a decrease in information asymmetry good news?

Releasing results on clinical trials allows academics and practitioners to crosscheck those results with their own findings and real-life cases. This leads to positive consequences due to a higher level of transparency, measured in our study by increased public attention, a greater number of public complaints reports and recalls for safety reasons.

 

This leads to positive consequences due to a higher level of transparency, measured in our study by increased public attention, a greater number of public complaints reports and recalls for safety reasons.

 

Indeed, in our study, we observed an increased number of adverse event and product problem complaint reports to the FDA as well as drug and medical device recalls for affected companies after the FDAAA was implemented. We attributed this finding to increased transparency and public monitoring.

microscope
"We've found an increased number of adverse event and product problem complaint reports to the FDA as well as drug and medical device recalls for affected companies after the FDAAA was implemented."
(Photo Credits: ©H Ko on Adobe Stock)

Why would better access to clinical trial information be of interest to investors?

Information helps capital market participants to assess a company's competitive advantage. In the course of our research, an (anonymous) analyst covering pharmaceutical stocks on Wall Street told us that the disclosure of clinical trial outcomes constitutes a key source of information in forecasting the future revenues of the pharmaceutical companies conducting them.

 

The disclosure of clinical trial outcomes constitutes a key source of information in forecasting the future revenues of the pharmaceutical companies conducting them.

 

In our study, we analyzed the capital market responses through the bid-ask spread (a measure of information asymmetry), and our results reveal a significant decrease in bid-ask spreads after the FDAAA for companies affected by the FDAAA compared with other unaffected companies in the same industry or compared with matched similar companies outside the pharmaceutical industry. A lower bid-ask spread is usually linked to lower information asymmetry among capital market participants, which is reassuring for investors. All in all, we show that while the FDAAA is a legal requirement with low enforcement and compliance – only around 40% of applicable clinical trial results get published on the ClinicalTrials.gov website between 2007 and 2013 – there are still some benefits to be derived from its implementation for both investors and the general public.

 

Article based on the research "Consequences of Disclosing Clinical Trial Results: Evidence from the Food and Drug Administration Amendments Act” by Thomas Bourveau (Columbia Business School, HEC Paris Ph.D. alumnus), Vedran Capkun (HEC Paris) and Yin Wang (Singapore Management University, HEC Paris Ph.D. alumnus). When a Ph.D. at HEC Paris, Yin Wang was awarded the HEC Foundation Award for the best HEC thesis in 2018.

Related content on Accounting

Luc Paugam HEC professor
Luc Paugam
Associate Professor, Mazars “Purposeful Governance” Chair
Accounting

Is the Global Convergence of Sustainability Reporting Possible?

By Hervé Stolowy, Luc Paugam

Accounting

What Influences Pharmaceutical Companies to Disclose Clinical Trial Results... Or Not?

By Vedran Capkun, Yin Wang

Helene Loning - HEC Paris
Hélène Löning
Associate Professor and Academic Director
Accounting

Cryptocurrency Affair Reflects Complex Interplay between Off-Chain Practices and Blockchain Accounting

By Dane Pflueger

Subscribe button for Knowledhe@HEC newsletter

Newsletter knowledge

A monthly brief in your email box and 3 issues of the book per year.

follow us

Insights @HECParis School of #Management

Follow Us

Support Research

Our articles are produced thanks to our reader's support